Global Angioplasty Balloons Market is expected to grow at a significant CAGR in the forecast period 2018 to 2025. The new market report contains data for historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025
.
Access Full Report: https://databridgemarketresearch.com/reports/global-angioplasty-balloons-market
The global angioplasty balloons market highly concentrated to a few big players and rest to local players who cater to domestic markets only. Angioplasty balloons market is dominated by Medtronic accounting for a highest market share in 2017, followed by C. R. Bard, Inc. and Boston Scientific Corporation among others.
Medtronic:
Founded in 1949, headquartered in Dublin (Ireland), Medtronic is a public owned company. Company is involved in researcher, designer, manufacturer, and seller of instruments or appliances that alleviate pain, restore health, and extend life. It operates in four segments that are Cardiac and Vascular Group (CVG), the Restorative Therapies Group (RTG), the Diabetes Group and the Minimally Invasive Therapies Group (MITG). It has 91,000 employees and has revenue of USD 29,710 Million in 2017.
In February 2017, QT Vascular (Singapore) has signed an agreement with Medtronic, for the distribution of its chocolate percutaneous transluminal angioplasty (PTA) catheter. This agreement will be valid for 5 years. The product will help Medtronic to sell the products for usage of atraumatic dilatation in the treatment of blocked arteries. The deal was done for USD 28 million.
Medtronic has its presence in Asia-Pacific , EMEA, America, Greater China. I has many subsidiaries in different locations such as Covidien Ltd. (Ireland), RF Surgical Systems(U.S.), Aptus Endosystems Inc (U.S.), Corventis, Inc. (U.S.), HeartWare Inc (U.S.), Vitatron N.V.(Netherlands), Xomed Australia PTY Limited (Australia) and others
- R. Bard, Inc.:
Founded in 1907, headquartered in New Jersey (U.S.), C. R. Bard, Inc. is a public owned company. Company is developer, manufacturer and marketer of medical products to aid in the diagnosis, treatment, repair, and long-term management of medical conditions associated with urology, oncology, and vascular disease, as well as surgical specialty areas. The company is offering their product category in vascular disease management, urology disease management, oncology disease management and surgical.
In December, BD acquired C.R. Bard (U.S.), a company engaged in the development, manufacturing and marketing of medical technologies. The acquisition was intended to create a new health care industry leader in the global market.
- R. Bard, Inc. has its presence in North America, Europe, Middle East, and Asia (EMEA). I has many subsidiaries in different locations such as Bard Medical Division(U.S.), Liberator Medical Holdings, Inc.(U.S.), Davol Inc (U.S.) and Bard Access Systems, Inc (U.S.) among others.
Boston Scientific Corporation:
Boston Scientific Corporation was incorporated in 1974 and headquartered in Massachusetts, U.S. The company is a providing products and service with the less invasive technologies for diagnosing and treating endoscopy, interventional cardiology, neuromodulation, peripheral interventions, rhythm management, urology and pelvic health medical conditions. It operates their business through three segments namely - Cardiovascular, Rhythm Management And Medsurg.
In October, Boston Scientific Corporation (U.S.) acquired Apama Medical (U.S.), which is a developer of Apama Radiofrequency (RF) Balloon Catheter Systems to treat atrial fibrillation. With this acquisition the company has strengthened its electrophysiology portfolio and extended into single-shot balloon pulmonary vein isolation treatments for patients suffering from atrial fibrillation,
Boston Scientific Corporation operates in U.S. and internationally in other countries along with its subsidiaries such as Guidant Corporation (U.S.), Cardiac Pacemakers, Inc.(U.S.), American Medical Systems Inc (U.S.) and Atritech, Inc.(U.S.) among others
